TEMOZOLOMIDE IN PEDIATRIC/ADOLESCENT PATIENTS WITH PROGRESSIVE CANCER

替莫唑胺治疗儿童/青少年进展性癌症患者

• 批准号: 6246765
• 负责人: JAMES A WHITLOCK
• 金额: $ 3.1万
• 依托单位: VANDERBILT UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-01-27 至 1997-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6246765
• 关键词: adolescence (12-20); antineoplastics; child (0-11); clinical research; drug administration rate /duration; drug adverse effect; human subject; neoplasm /cancer chemotherapy; neoplasm /cancer invasiveness; pediatric neoplasm /cancer; pediatric pharmacology; pharmacokinetics

This study is to determine the maximum tolerable dose (MTD) of oral temozolomide given daily for 5 days. We also want to determine the toxicities of temozolomide given on this schedule and the pharmacokinetic behavior of temozolomide administered orally for five consecutive days in pediatric and adolescent patients.

本研究旨在确定口服的最大耐受量。 替莫唑胺每日给药，连续5天。我们还想确定 本附表所列替莫唑胺的毒性和 替莫唑胺口服5次的药代动力学行为 儿科和青少年患者连续服药数天。